IP Library › Granted Patent US 8,097,700
Granted Patent B2
US 8,097,700 · App. 12/702,086 · Granted Jan 17, 2012

TAT294 polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,700
App. No.
12/702,086
Granted
Jan 17, 2012
Kind
B2
Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Claims (23)

1. An isolated polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2),

(b) the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2), lacking its associated signal peptide,

(c) the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127, or

(d) the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127, lacking its associated signal peptide;

wherein said isolated polypeptide can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO:2 in breast tissue samples.

2. A chimeric molecule comprising a polypeptide according to claim 1 fused to a heterologous amino acid sequence.

3. The chimeric molecule of claim 2 , wherein said heterologous amino acid sequence is an epitope tag sequence.

4. The chimeric molecule of claim 2 , wherein said heterologous amino acid sequence is an Fc region of an immunoglobulin.

5. The isolated polypeptide of claim 1 comprising an amino acid sequence having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2),

(b) the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2), lacking its associated signal peptide,

(c) the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127, or

(d) the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127, lacking its associated signal peptide.

6. The isolated polypeptide of claim 1 comprising:

(a) the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2),

(b) the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2), lacking its associated signal peptide,

(c) the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127, or

(d) the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127, lacking its associated signal peptide.

7. The isolated polypeptide of claim 6 comprising the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2).

8. The isolated polypeptide of claim 6 comprising the amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO:2), lacking its associated signal peptide.

9. The isolated polypeptide of claim 6 comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127.

10. The isolated polypeptide of claim 6 comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA deposited under ATCC Accession No. 203127, lacking its associated signal peptide.